Sugi Predict

Sugi Predict / Compounds / SCHEMBL6225564

SCHEMBL6225564

SCHEMBL6225564

CN(C)c1cc(F)cc(F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 5/20 0.42
▸ ALDH1A1 P00352 5/20 0.42
▸ ALOX15 P16050 2/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ APP P05067 3/20 0.41
▸ CA12 O43570 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ CYP3A4 P08684 2/20 0.33
▸ MAPK1 P28482 2/20 0.33
▸ TDP1 Q9NUW8 2/20 0.33
▸ TERT O14746 1/20 0.33
▸ CES2 O00748 1/20 0.33
▸ CES1 P23141 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ CHRM5 P08912 1/20 0.33
▸ CHKA P35790 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1724944 0.84 TSHR (0.41) TSHRALDH1A1ALOX15HSD17B10APP
SCHEMBL22250113 0.82 RAPGEF4 (0.36) TSHRALDH1A1ALOX15HSD17B10APP
SCHEMBL14941294 0.82 TSHR (0.34) TSHRALDH1A1ALOX15HSD17B10APP
SCHEMBL15928724 0.82 ALDH1A1 (0.42) TSHRALDH1A1ALOX15HSD17B10APP
SCHEMBL16404641 0.82 TSHR (0.34) TSHRALDH1A1ALOX15HSD17B10APP
SCHEMBL10344905 0.82 CA12 (0.55) TSHRALDH1A1ALOX15HSD17B10APP
SCHEMBL3750531 0.82 CHRNB4 (0.35) TSHRALDH1A1ALOX15HSD17B10APP
SCHEMBL12879930 0.81 CA12 (0.38) APPCA12CA1CA9CES2
SCHEMBL10623333 0.78 TSHR (0.33) TSHRALDH1A1ALOX15HSD17B10APP
SCHEMBL1760716 0.75 TSHR (0.57) TSHRALDH1A1ALOX15HSD17B10APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-1146847-A — — None — — JP disclosed
US-12030853-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2024-07-09 — — US disclosed
CN-118047736-A Synthesis method of 2,2', 6' -tetrafluoro- [1,1' -biphenyl ] compounds 广州佳途科技股份有限公司 2024-05-17 — — CN disclosed
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2023-10-26 — — US disclosed
EP-4010080-B1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LTD (GB) 2023-09-27 — — EP disclosed
US-20230242503-A9 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2023-08-03 — — US disclosed
US-20230242503-A9 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2023-08-03 — — US disclosed
US-20220298134-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2022-09-22 — — US disclosed
US-20210171461-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION 2021-06-10 — — US disclosed
WO-2021096496-A1 METHODS FOR FORMING ARYL CARBON-NITROGEN BONDS USING LIGHT AND PHOTOREACTORS USEFUL FOR CONDUCTING SUCH REACTIONS COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2021-05-20 — — WO disclosed
US-20040209897-A1 Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds PHARMACIA CORPORATION 2004-10-21 — — US disclosed
WO-2004058762-A1 MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS PHARMACIA CORPORATION (US) 2004-07-15 — — WO disclosed
US-6337297-B1 CHROMIUM CATALYST FOR TRIMERIZATION OF ETHYLENE WITH MULTIDENTATE LIGAND OR HALOGEN, CARBOXY GROUP TOSOH CORPORATION (JP) 2002-01-08 — — US disclosed
CN-1067069-C Bicycle amines as insecticides ZENECA LTD (GB) 2001-06-13 — — CN disclosed
CN-1218470-A Bicycle amines as insecticides ZENECA LTD (GB) 1999-06-02 — — CN disclosed
EP-0901490-A1 BICYCLIC AMINES AS INSECTICIDES ZENECA LIMITED (GB) 1999-03-17 — — EP disclosed
WO-1997043286-A1 BICYCLIC AMINES AS INSECTICIDES ZENECA LIMITED (GB) 1997-11-20 — — WO disclosed
US-5169987-A Light sensitive charge generating compounds for electrography FUJI XEROX CO., LTD. (JP) 1992-12-08 — — US disclosed
US-5047589-A Electrophotographic light-sensitive material containing squarylium compound FUJI XEROX CO. LTD. (JP) 1991-09-10 — — US disclosed
JP-H01146847-A NOVEL SQUARYLIUM COMPOUND AND PRODUCTION THEREOF FUJI XEROX CO LTD 1989-06-08 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 IKZF1, IKZF3, IKZF2 TSHR 2238/4885ALDH1A1 4344/4885ALOX15 3282/4885
US-20230242503-A9 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER SDHA, SDHB, NQO1 TSHR 3400/4885ALDH1A1 97/4885ALOX15 781/4885
US-20040209897-A1 Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds MAPKAPK2, MAP3K2, MKNK2 TSHR 3883/4885ALDH1A1 4638/4885ALOX15 3087/4885
US-20220298134-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER SDHA, SDHB, NQO1 TSHR 3400/4885ALDH1A1 97/4885ALOX15 781/4885
US-12030853-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 TSHR 3550/4885ALDH1A1 4709/4885ALOX15 3975/4885
US-20210171461-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 TSHR 3550/4885ALDH1A1 4709/4885ALOX15 3975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.